- Home
- AMP vs TAK Comparison
AMP vs TAK Comparison
Compare AMP & TAK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMP
- TAK
- Stock Information
- Founded
- AMP 1894
- TAK 1781
- Country
- AMP United States
- TAK Japan
- Employees
- AMP N/A
- TAK N/A
- Industry
- AMP Investment Managers
- TAK Biotechnology: Pharmaceutical Preparations
- Sector
- AMP Finance
- TAK Health Care
- Exchange
- AMP Nasdaq
- TAK Nasdaq
- Market Cap
- AMP 44.9B
- TAK 47.0B
- IPO Year
- AMP 2005
- TAK N/A
- Fundamental
- Price
- AMP $492.27
- TAK $14.37
- Analyst Decision
- AMP Hold
- TAK
- Analyst Count
- AMP 6
- TAK 0
- Target Price
- AMP $514.60
- TAK N/A
- AVG Volume (30 Days)
- AMP 458.9K
- TAK 2.0M
- Earning Date
- AMP 04-24-2025
- TAK 05-08-2025
- Dividend Yield
- AMP 1.30%
- TAK 4.08%
- EPS Growth
- AMP 0.13
- TAK N/A
- EPS
- AMP 29.43
- TAK 0.45
- Revenue
- AMP $18,082,000,000.00
- TAK $30,595,075,281.00
- Revenue This Year
- AMP N/A
- TAK $0.87
- Revenue Next Year
- AMP $4.44
- TAK $1.69
- P/E Ratio
- AMP $16.71
- TAK $63.69
- Revenue Growth
- AMP 9.09
- TAK 7.45
- 52 Week Low
- AMP $385.74
- TAK $12.58
- 52 Week High
- AMP $582.05
- TAK $15.37
- Technical
- Relative Strength Index (RSI)
- AMP 57.81
- TAK 40.48
- Support Level
- AMP $471.76
- TAK $14.22
- Resistance Level
- AMP $485.90
- TAK $15.43
- Average True Range (ATR)
- AMP 12.60
- TAK 0.20
- MACD
- AMP 3.66
- TAK -0.08
- Stochastic Oscillator
- AMP 94.03
- TAK 11.98
About AMP Ameriprise Financial Inc.
Ameriprise Financial is a major player in the US market for asset and wealth management, with around $1.5 trillion in total assets under management and administration at the end of 2024. With about 10,500 advisors, Ameriprise has one of the largest branded advisor networks in the industry. About 80% of the company's revenue comes from its asset and wealth management segments. Ameriprise has reduced its exposure to insurance with the sale of its auto and home insurance business in 2019 and discontinuing the sale of proprietary fixed annuities in 2020.
About TAK Takeda Pharmaceutical Company Limited (each representing 1/2 of a share of)
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.3 trillion in fiscal 2023. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with 50% derived from the US, 20% from Japan, 20% from Europe and Canada.